# Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct01954992/  
OnCo record `nct01954992` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Glufosfamide in pancreatic ductal adenocarcinoma, run by Eleison Pharmaceuticals LLC., now recruiting.

## Summary

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT01954992 by Eleison Pharmaceuticals LLC., with 480 participants planned, started 2014-04 and due to reach its primary completion in 2026-06. Interventions recorded: Glufosfamide and Fluorouracil.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01954992
- Phase: 3
- Setting: A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
- Sponsor: Eleison Pharmaceuticals LLC.
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT01954992: https://clinicaltrials.gov/study/NCT01954992

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct01954992.json